Our results showed that (Figures 2A, B) subcutaneous administration of GAD65 vaccine, or GAD65 vaccine + Kyn, prevented the development of hyperglycemia in 50% (3/6) and 67% (4/6) of NOD mice at least one-month (from the 14th week to 18th week), respectively. This evidence concerns the gene GAD2 and Hyperglycemia.